




RealRate

PHARMACEUTICAL 2017

Axsome Therapeutics Inc
Rank 195 of 308



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Axsome Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Axsome Therapeutics Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 67% points. The greatest weakness of Axsome Therapeutics Inc is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 61% points.

The company's Economic Capital Ratio, given in the ranking table, is 208%, being 37% points below the market average of 245%.

Input Variable	Value in 1000 USD
Assets, Current	37,999
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	7,171
Liabilities, Non-Current	9,470
Other Assets	113
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	342
Other Revenues	0
Property and Equipment	101
Research and Development	21,200
Selling, General and Administrative Expense	6,344

Output Variable	Value in 1000 USD
Assets	38,213
Liabilities	16,641
Expenses	27,544
Revenues	0
Stockholders Equity	21,571
Net Income	-27,202
Comprehensive Net Income	-27,202
BaseVar	41,370
ECR before LimitedLiability	72%
Economic Capital Ratio	208%